SCHEMBL17857686

SCHEMBL17857686

CO/C=C(/OC)C(=O)OC

nearest known ligand 0.38

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
KEAP1 Q14145 1/20 0.35
NFE2L2 Q16236 1/20 0.35
HCAR2 Q8TDS4 1/20 0.35
TET2 Q6N021 1/20 0.31
EGLN1 Q9GZT9 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
ATP6V1B1 P15313 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26171166 1.00 ALDH1A1 (0.38) ALDH1A1KEAP1NFE2L2HCAR2TET2
SCHEMBL10782279 1.00 ALDH1A1 (0.38) ALDH1A1KEAP1NFE2L2HCAR2TET2
SCHEMBL27576915 0.80 ATP6V1B1 (0.38) ATP6V1B1
SCHEMBL29088449 0.79
SCHEMBL27677617 0.79 GAA (0.41) ALDH1A1HCAR2EGLN1MAPT
SCHEMBL17837860 0.78
SCHEMBL28781856 0.78
SCHEMBL17837861 0.78
SCHEMBL2539106 0.78
SCHEMBL16440972 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270222-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF SATELLOS BIOSCIENCE INC. (CA) 2025-08-28 US disclosed
US-20250122207-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF SATELLOS BIOSCIENCE INC. (CA) 2025-04-17 US disclosed
WO-2025054448-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF SATELLOS BIOSCIENCE INC. (CA) 2025-03-13 WO disclosed
US-9593097-B2 Axl inhibitors PFIZER INC. (US) 2017-03-14 US disclosed
US-9593097-B2 Axl inhibitors PFIZER INC. (US) 2017-03-14 US disclosed
WO-2016097918-A1 PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS PFIZER INC. (US) 2016-06-23 WO disclosed
US-20160176850-A1 AXL INHIBITORS PFIZER INC. 2016-06-23 US disclosed
US-20160176850-A1 AXL INHIBITORS PFIZER INC. 2016-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122207-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF AAK1, CAMKK1, AP2A1 ALDH1A1 3638/4885KEAP1 2082/4885NFE2L2 1664/4885
US-20160176850-A1 AXL INHIBITORS AXL, FLT3, MERTK ALDH1A1 4703/4885KEAP1 3614/4885NFE2L2 3646/4885
US-20250270222-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF AAK1, AP2A1, CSNK1A1 ALDH1A1 3210/4885KEAP1 1938/4885NFE2L2 1757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.